๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Treatment of chronic hepatitis B

โœ Scribed by Stephanie D. Straley; Norah A. Terrault

Book ID
107540370
Publisher
Current Science Inc.
Year
2003
Tongue
English
Weight
378 KB
Volume
2
Category
Article
ISSN
1540-3416

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Treatment of chronic hepatitis B
Treatment of chronic hepatitis B
โœ Gary L. Davis ๐Ÿ“‚ Article ๐Ÿ“… 1991 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 365 KB

Treatment of Chronic Hepatitis B Chronic HBV infection is common and affects more than 200 million individuals worldwide. It is estimated that more than 1 million persons in the United States alone are Chronically infected with this virus. Fur-

Treatment of chronic hepatitis B
Treatment of chronic hepatitis B
โœ P. Marcellin; T. Asselah; N. Boyer ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 244 KB
Lamivudine treatment of chronic hepatiti
Lamivudine treatment of chronic hepatitis B
โœ Geoffrey Dusheiko ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 142 KB ๐Ÿ‘ 1 views
Thymic factor X treatment of chronic hep
Thymic factor X treatment of chronic hepatitis B
โœ Janusz Cianciara; Tomasz Laskus ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 186 KB

We read with interest the report of Mutchnick et al. 1 I on the effectiveness of thymosin therapy for chronic hepatitis B. Both in this paper and in the accompanying editorial (2), the authors cite the study by Dabrowslu et al. (31, which described the ability of thymic factor X (TFX), an extract of

Recombinant leukocyte interferon treatme
Recombinant leukocyte interferon treatment of chronic hepatitis B
โœ Geoffrey Dusheiko; Adrian Dibisceglie; Sheila Bowyer; Evelyn Sachs; Marian Ritch ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 513 KB

We have investigated the efficacy of a relatively prolonged course of recombinant leukocyte interferon treatment in 14 chronic HBsAg-, HBeAg-, hepatitis B virus DNA-and DNA polymerasepositive carriers. a-Interferon was administered for 9 weeks. Six of 14 treated carriers have a sustained loss of HBe